



#20/ RCE  
RCE/600

PTO/SB/30 (05-03)

Approved for use through 4/30/2003 OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:  
Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Application Number	09/383,894
Filing Date	August 26, 1999
First Named Inventor	Ming Li
Art Unit	1635
Examiner Name	K. Lacourciere
Attorney Docket Number	004.00191

RECEIVED  
JUL 16 2003  
TECH CENTER 1600/2900

**This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application**  
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

## 1. Submission required under 37 CFR 1.114

Note: If the RCE is proper, any previously filed unentered and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such

- a. ☒ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
- i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- ii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply      iii. ☒ Information Disclosure Statement (IDS)
- ii. ☐ Affidavit(s)/Declaration(s)      iv. ☐ Other \_\_\_\_\_

## 2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other \_\_\_\_\_

## 3. Fees

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 50-0772 07/14/2003 SDIRETA1 00000051 09383894
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17) 01 FC:2801 375.00 0P
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Check in the amount of \$ 580 enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print / Type)

Karla M. Weyand

Registration No. (Attorney / Agent)

40,223

Signature

*Karla M. Weyand*

Date

July 7, 2003

## CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print / Type)

Karla M. Weyand

Signature

*Karla M. Weyand*

Date

July 7, 2003

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



004.00191

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ming Li )  
Serial No.: 09/383,894 )  
Filed: August 26, 1999 )  
For: T-TYPE CALCIUM CHANNEL )

Examiner: K.  
Lacourciere  
Art Unit: 1635

#21/12.T.  
7/18  
w/ drugs  
improper

RECEIVED  
JUL 16 2003  
TECH CENTER 1600/2900

AMENDMENT

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450  
MS RCE

Sir:

Please amend the subject application as follows:

In the Claims:

Please amend claim 43 as follows:

43. (Amended) A method of modifying insulin secretion by pancreatic beta cells in vitro, the method comprising modifying levels of functional T type calcium channels in the in vitro pancreatic beta cells.

Pursuant to 37 CFR \$1.121(c)(1)(ii), a marked up version of this claim accompanies this amendment.

REMARKS

Applicant respectfully requests that the rejections of the claims be reconsidered and withdrawn in view of the above amendments and the following remarks.

The rejection of claims 43-49 under 35 U.S.C. \$112, first paragraph, for lack of enablement is respectfully traversed.